Revision as of 12:37, 1 June 2018 edit Beevil (talk \| contribs) Extended confirmed users 2,588 edits →Lutathera: see also: PRRT ← Previous edit		Revision as of 03:21, 18 August 2018 edit undo Michipedian (talk \| contribs) Extended confirmed users 24,446 edits m boldface fix Next edit →
Line 11: \|___location = Saint-Genis-Pouilly, France }} '''Advanced Accelerator Applications''' ('''AAA)''') is a [[pharmaceutical]] group specialized in the field of [[nuclear medicine]].<ref name="AAA1">[http://www.privateequitywire.co.uk/2014/02/18/197348/advanced-accelerator-applications-completes-eur41m-fundraising PrivateEquityWire, "Advanced Accelerator Applications completes fundraising", Feb 18th, 2014]</ref> The group operates in all three segments of nuclear medicine ([[Positron emission tomography\|PET]], [[SPECT]] and therapy) to diagnose and treat serious conditions in the fields of [[oncology]], [[neurology]], [[cardiology]], infectious and inflammatory [[diseases]].<ref name="AAA2">[http://www.ilsole24ore.com/art/impresa-e-territori/2014-03-12/dal-cern-biopark-canavese-064227.shtml?uuid=ABvohR2&fromSearch Il Sole 24 Ore, “Dal Cern and Biopark canavese”, March 12th, 2014]</ref>

Advanced Accelerator Applications: Difference between revisions